ES2175433T3 - Composiciones indicadas para la administracion de genes en celulas epiteliales. - Google Patents

Composiciones indicadas para la administracion de genes en celulas epiteliales.

Info

Publication number
ES2175433T3
ES2175433T3 ES97930669T ES97930669T ES2175433T3 ES 2175433 T3 ES2175433 T3 ES 2175433T3 ES 97930669 T ES97930669 T ES 97930669T ES 97930669 T ES97930669 T ES 97930669T ES 2175433 T3 ES2175433 T3 ES 2175433T3
Authority
ES
Spain
Prior art keywords
genes
administration
epithelial cells
compositions indicated
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97930669T
Other languages
English (en)
Inventor
Lisbeth Illum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Services Ltd
Original Assignee
West Pharmaceutical Services Drug Delivery and Clinical Research Center Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614441.5A external-priority patent/GB9614441D0/en
Priority claimed from GBGB9614471.2A external-priority patent/GB9614471D0/en
Application filed by West Pharmaceutical Services Drug Delivery and Clinical Research Center Ltd filed Critical West Pharmaceutical Services Drug Delivery and Clinical Research Center Ltd
Application granted granted Critical
Publication of ES2175433T3 publication Critical patent/ES2175433T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Optics & Photonics (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Electrotherapy Devices (AREA)
  • Prostheses (AREA)

Abstract

Una composición que comprende un complejo particulado de quitosano y ADN, siendo el complejo de entre 10 nm y 1 {mi}m de tamaño y llevando una carga superficial.
ES97930669T 1996-07-10 1997-07-10 Composiciones indicadas para la administracion de genes en celulas epiteliales. Expired - Lifetime ES2175433T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9614441.5A GB9614441D0 (en) 1996-07-10 1996-07-10 Gene therapy delivery system for targeting to the lung endothelia
GBGB9614471.2A GB9614471D0 (en) 1996-07-10 1996-07-10 Gene delivery to epithelial cells

Publications (1)

Publication Number Publication Date
ES2175433T3 true ES2175433T3 (es) 2002-11-16

Family

ID=26309674

Family Applications (2)

Application Number Title Priority Date Filing Date
ES97930670T Expired - Lifetime ES2175434T3 (es) 1996-07-10 1997-07-10 Sistema de suministros de terapia de genes para dirigir al endotelio.
ES97930669T Expired - Lifetime ES2175433T3 (es) 1996-07-10 1997-07-10 Composiciones indicadas para la administracion de genes en celulas epiteliales.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES97930670T Expired - Lifetime ES2175434T3 (es) 1996-07-10 1997-07-10 Sistema de suministros de terapia de genes para dirigir al endotelio.

Country Status (13)

Country Link
EP (2) EP0994726B1 (es)
JP (2) JP2001500109A (es)
KR (2) KR20000067855A (es)
AT (2) ATE216264T1 (es)
AU (2) AU720989B2 (es)
CA (2) CA2257300A1 (es)
DE (2) DE69712110T2 (es)
DK (1) DK0986404T3 (es)
ES (2) ES2175434T3 (es)
GB (2) GB2330532A (es)
NO (2) NO990002D0 (es)
PT (2) PT986404E (es)
WO (2) WO1998001161A2 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
JPH11246392A (ja) * 1998-03-03 1999-09-14 Makoto Otsuka 経口用固形製剤
AU3898699A (en) * 1998-05-13 1999-11-29 Regents Of The University Of Michigan, The Sustained dna delivery from structural matrices
CA2369451C (en) 1999-04-08 2009-09-22 Genentech, Inc. Composition based on oppositely-charged polypeptides
DE19940795A1 (de) 1999-08-27 2001-03-01 Lohmann Therapie Syst Lts Schnellzerfallende Pellets auf der Basis von Chitosan
SE9904121D0 (sv) * 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
ATE277684T1 (de) * 1999-11-18 2004-10-15 Cognis Iberia Sl Mikrokapseln
FR2801811B1 (fr) * 1999-12-06 2002-05-03 Gerard Habar Procede de fabrication de microcapsules portant des charges cationiques
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7442388B2 (en) 2000-05-10 2008-10-28 Weers Jeffry G Phospholipid-based powders for drug delivery
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
AU8737501A (en) * 2000-09-14 2002-03-26 Austin Research Inst Composition comprising immunogenic microparticles
CN1543338B (zh) 2001-08-16 2010-06-16 Cmp医疗有限公司 壳多糖微粒及其医疗用途
WO2003028657A2 (en) * 2001-10-03 2003-04-10 The Johns Hopkins University Compositions for oral gene therapy and methods of using same
US7368102B2 (en) 2001-12-19 2008-05-06 Nektar Therapeutics Pulmonary delivery of aminoglycosides
NO317653B1 (no) 2002-05-03 2004-11-29 Stiftelsen Biopolymer Formulering som omfatter komplekser av kitosanoligomerer og nukleinsyre, fremgangsmate for a fremstille formuleringen samt anvendelser derav.
AU2003253508A1 (en) * 2002-07-15 2004-02-02 Feyecon Development And Implementation B.V. Method for particle precipitation using near-critical and supercritical antisolvents
US20040014698A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
US20040048260A1 (en) * 2002-09-10 2004-03-11 Fu-Hsiung Chang Transfection of nucleic acid
US20040133099A1 (en) 2002-12-18 2004-07-08 Dyer R. Kent Otologic nanotechnology
US8651113B2 (en) 2003-06-18 2014-02-18 Swr&D Inc. Magnetically responsive nanoparticle therapeutic constructs and methods of making and using
US7344491B1 (en) 2003-11-26 2008-03-18 Nanobiomagnetics, Inc. Method and apparatus for improving hearing
US7723311B2 (en) 2003-06-18 2010-05-25 Nanobiomagnetics, Inc. Delivery of bioactive substances to target cells
DE10329087B4 (de) * 2003-06-27 2014-02-13 Biomedical International R + D Gmbh Antigenhaltige Mikrosphären zur Allergietherapie
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
JP4674288B2 (ja) * 2004-03-31 2011-04-20 恵雄 岡畑 歯科用材料。
US7282194B2 (en) * 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
AU2007285472B2 (en) 2006-03-30 2013-10-24 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
JP2009532466A (ja) * 2006-04-04 2009-09-10 エスティーシー．ユーエヌエム 薬物送達用の膨潤性粒子
EP2164964B1 (en) * 2007-07-06 2011-09-07 Aarhus Universitet Dehydrated chitosan nanoparticles
SI2195035T1 (en) * 2007-09-28 2018-05-31 Engene, Inc. High concentrations of chitosan-nucleic acid polypeptics of composites
JP5841708B2 (ja) * 2008-07-01 2016-01-13 日東電工株式会社 表面被覆微粒子の医薬組成物
CN101869704A (zh) * 2010-06-08 2010-10-27 中国药科大学 单剂免疫破伤风类毒素阳离子葡聚糖微球及其制备方法
US8802076B2 (en) 2010-10-04 2014-08-12 Duke University Compositions and methods for modulating an immune response
WO2021150997A2 (en) * 2020-01-22 2021-07-29 Engene, Inc. Localized expression of therapeutic nucleic acids in lung epithelial cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046750A (en) * 1974-09-30 1977-09-06 California Institute Of Technology Ionene modified small polymeric beads
JPH03198782A (ja) * 1989-12-27 1991-08-29 Bitamin Kenkyusho:Kk 遺伝子導入用キャリアー、該キャリアーと遺伝子との複合体及び細胞への遺伝子導入法
US5972600A (en) * 1992-04-03 1999-10-26 The Regents Of The University Of California Separation of active complexes
EP0769063A1 (en) * 1994-06-27 1997-04-23 The Johns Hopkins University Targeted gene delivery system
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
FR2724935B1 (fr) * 1994-09-27 1996-12-20 Centre Nat Rech Scient Compositions nanoparticulaires contenant des derives nucleotidiques, leur preparation et leur emploi en therapeutique
KR960016882A (ko) * 1994-11-01 1996-06-17 강재헌 치주염치료를 위한 서방출형 생분해성 제제
ATE252894T1 (de) * 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung

Also Published As

Publication number Publication date
GB9900048D0 (en) 1999-02-24
PT994726E (pt) 2002-09-30
JP2000514086A (ja) 2000-10-24
AU720989B2 (en) 2000-06-22
DE69712108T2 (de) 2002-12-12
EP0986404B1 (en) 2002-04-17
GB2330532A (en) 1999-04-28
PT986404E (pt) 2002-09-30
WO1998001161A3 (en) 1998-03-12
WO1998001160A3 (en) 1998-03-05
NO990002L (no) 1999-01-04
JP2001500109A (ja) 2001-01-09
WO1998001160A2 (en) 1998-01-15
NO990003D0 (no) 1999-01-04
GB9900054D0 (en) 1999-02-24
EP0994726B1 (en) 2002-04-17
DK0986404T3 (da) 2002-05-13
ATE216265T1 (de) 2002-05-15
ES2175434T3 (es) 2002-11-16
EP0986404A2 (en) 2000-03-22
AU726518B2 (en) 2000-11-09
AU726518C (en) 2002-01-03
CA2257300A1 (en) 1998-01-15
EP0994726A2 (en) 2000-04-26
AU3454697A (en) 1998-02-02
KR20000023716A (ko) 2000-04-25
GB2330534B (en) 2000-09-06
CA2257408A1 (en) 1998-01-15
NO990002D0 (no) 1999-01-04
DE69712108D1 (de) 2002-05-23
DE69712110D1 (de) 2002-05-23
NO990003L (no) 1999-01-04
GB2330534A (en) 1999-04-28
ATE216264T1 (de) 2002-05-15
DE69712110T2 (de) 2002-12-12
KR20000067855A (ko) 2000-11-25
WO1998001161A2 (en) 1998-01-15
AU3454597A (en) 1998-02-02

Similar Documents

Publication Publication Date Title
NO990002L (no) Blandinger for administrasjon av gener
AR006265A1 (es) Una composicion para el cuidado del cabello y un metodo para acondicionar y modelar el cabello
ES2132758T5 (es) Nucleo de articulos absorbentes estirables.
EP1294097A3 (en) Input/output buffer supporting multiple I/O standards
FR2732967B1 (fr) 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
ATE331783T1 (de) Trockene mikroorganismenkulturen und verfahren zu deren herstellung
NZ306653A (en) Isolated dna il-17 receptors
CA2279270A1 (en) Polyesteramides with amino acid-derived groups alternating with alpha-hydroxyacid-derived groups and surgical articles made therefrom
EP0809997A3 (en) Medical device with biomolecule-coated surface graft matrix
WO2005015579A3 (en) Methods of forming three-dimensional nanodot arrays in a matrix
CO4970766A1 (es) Composiciones para el cuidado de la piel y metodo para mejo- rar la apariencia de la piel
TR199902655A2 (xx) K�k�rt-fonksiyonel poliorganosiloksanlar
ES2136161T3 (es) Producto en forma solida para la xerostomia.
EP1313439A4 (en) METHOD FOR PRODUCING TOOTHPASTS AND RECEIVED PRODUCTS
CA95794S (en) Paving stone
IT1290856B1 (it) Metalloceni, loro preparazione ed uso nella polimerizzazione di alfa-olefine
AU6145190A (en) New functional bacillus thuringiensis hybrid genes obtained by in vivo recombination
CA2295321A1 (en) Isolated nona- and decapeptides which bind to hla molecules, and the use thereof
AR030497A1 (es) Suspension abrasiva fluida para usar en dentifricos
FI963924A7 (fi) Geeni, joka antaa hiivalle kyvyn flokkuloitua, ja geenituote
ES2136969T3 (es) Metodo y composicion para proporcionar un revestimiento de barrera a vapores humedos y apto para ser reducido de nuevo a pasta papelera, para envases flexibles.
ATE214263T1 (de) Flüssigkeitsabgabesystem
AU1227699A (en) Oxyranyle-triazoline thiones and their use as microbicides
BR9713539A (pt) Composições de tratamento de solos, seu processo de prepararo e sua utilização.
UA48245C2 (uk) ЗАМІЩЕНІ 1,2,3,4-ТЕТРАГІДРО-2-ДИБЕНЗОФУРАНАМІНИ ТА 2-АМІНОЦИКЛОГЕПТА[B]БЕНЗОФУРАНИ, ФАРМАЦЕВТИЧНА ЛІКАРСЬКА ФОРМА ТА СПОСІБ ПІДВИЩЕННЯ АКТИВАЦІЇ 5-НТ<sub>1F</sub> РЕЦЕПТОРА У ССАВЦЯ

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 994726

Country of ref document: ES